Research Article
Ductal Breast Carcinoma In Situ: Mammographic Features and Its Relation to Prognosis and Tumour Biology in a Population Based Cohort
Table 1
Baseline patient and tumour characteristics in a DCIS cohort diagnosed between 1986 and 2004, by mammographic features (
).
| Ductal carcinoma in situ | Mammographic features | value | Stellate | Circular or oval shaped | Powdery calcifications | Crushed stone calcifications | Casting type calcifications | Galactographic finding | Architectural distortion | Normal mammography |
| Numbers at risk () | 16 | 47 | 29 | 192 | 89 | 15 | 28 | 16 | | Age (mean, years) | 64.3 | 64.2 | 52.0 | 55.6 | 56.5 | 55.9 | 65.4 | 56.4 | 0.36 | Detection mode | | | | | | | | | | Screening | 10 (62.5%) | 27 (57.4%) | 24 (82.8%) | 173 (90.1%) | 82 (92.1%) | 1 (6.7%) | 11 (39.3%) | 3 (20.0%) | <0.001 | Not screening | 6 (37.5%) | 20 (42.6%) | 5 (17.2%) | 19 (9.9%) | 7 (7.9%) | 14 (93.3%) | 17 (60.7%) | 12 (80.0%) | Type of surgery | | | | | | | | | | BCS | 14 (87.5%) | 40 (85.1%) | 25 (86.2%) | 159 (83.2%) | 64 (71.9%) | 9 (60.0%) | 18 (64.3%) | 12 (75.0%) | 0.06 | Mastectomy | 2 (12.5%) | 7 (14.9%) | 4 (13.8%) | 32 (16.8%) | 25 (28.1%) | 6 (40.4%) | 10 (35.7%) | 4 (25.0%) | Radiotherapy after BCS | | | | | | | | | | Yes | 4 (28.6%) | 14 (35.0%) | 13 (52.0%) | 73 (45.9%) | 34 (53.1%) | 5 (55.6%) | 6 (33.3%) | 4 (33.3%) | 0.42 | No | 10 (71.4%) | 26 (65.0%) | 12 (48.0%) | 86 (54.1%) | 30 (46.9%) | 4 (44.4%) | 12 (66.7%) | 8 (66.7%) | Nuclear grade | | | | | | | | | | 1 | 2 (12.5%) | 9 (19.1%) | 4 (13.8%) | 16 (8.3%) | 3 (3.4%) | 0 (0%) | 4 (14.3%) | 1 (6.2%) | <0.001 | 2 | 6 (37.5%) | 32 (68.1%) | 14 (48.3%) | 56 (29.2%) | 21 (23.6%) | 12 (80.0%) | 13 (46.4%) | 7 (43.8%) | 3 | 8 (50%) | 6 (12.8%) | 11 (37.9%) | 120 (62.5%) | 65 (73.0%) | 3 (20.0%) | 11 (39.3%) | 8 (50%) | Neoductgenesis | | | | | | | | | | 0–3p | 14 (93.3%) | 45 (100%) | 26 (89.7%) | 160 (85.6%) | 82 (92.1%) | 13 (86.7%) | 28 (100%) | 13 (81.2%) | 0.14 | 4–6p | 1 (6.7%) | 0 (0%) | 3 (10.3%) | 27 (14.4%) | 7 (7.9%) | 2 (13.3%) | 0 (0%) | 3 (18.8%) | ER | | | | | | | | | | ≥10% | 11 (73.3%) | 37 (88.1%) | 23 (71.9%) | 128 (74.4%) | 41 (52.6%) | 12 (85.7%) | 19 (67.9%) | 8 (53.3%) | <0.001 | <10% | 4 (26.7%) | 5 (11.9%) | 6 (28.1%) | 44 (25.6%) | 37 (47.4%) | 2 (14.3%) | 9 (32.1%) | 7 (46.7%) | PR | | | | | | | | | | ≥10% | 9 (60.0%) | 29 (67.4%) | 21 (72.4%) | 85 (50%) | 17 (23.3%) | 8 (61.5%) | 16 (61.5%) | 5 (33.3%) | <0.001 | <10% | 6 (40.0%) | 14 (32.6%) | 8 (27.6%) | 85 (50%) | 54 (76.7%) | 5 (38.5%) | 10 (38.5%) | 10 (66.7%) | HER2 | | | | | | | | | | positive | 4 (28.6%) | 1 (2.4%) | 24 (85.7%) | 63 (35.2%) | 41 (51.9%) | 3 (20.0%) | 4 (15.4%) | 6 (40.0%) | 0.002 | Normal | 10 (71.4%) | 41 (97.6%) | 4 (14.3%) | 113 (64.8%) | 38 (48.1%) | 12 (80.0%) | 22 (84.6%) | 9 (60.0%) | Proliferation | | | | | | | | | | High | 2 (15.4%) | 10 (27.0%) | 8 (34.8%) | 64 (40.3%) | 25 (36.8%) | 0 (0%) | 13 (48.1%) | 7 (46.7%) | 0.96 | Low | 11 (84.6%) | 27 (73.0%) | 15 (65.2%) | 95 (59.7%) | 43 (63.2%) | 11 (100%) | 14 (51.9%) | 8 (53.3%) | Tenascin-C | | | | | | | | | | High | 2 (28.6%) | 11 (34.4%) | 3 (15.0%) | 46 (36.2%) | 22 (36.7%) | 3 (30.0%) | 12 (52.2%) | 8 (72.7%) | 0.01 | Low | 5 (71.4%) | 21 (65.6%) | 17 (85.0%) | 81 (63. 8%) | 38 (63.3%) | 7 (70.0%) | 11 (47.8%) | 3 (27.3%) |
|
|
values are calculated for casting type calcification versus all other types of mammographic features together. Breast conserving surgery = BCS.
|